Donate

New Data Supports Safety & Efficacy Claims of ALPROLIX

August 17, 2015

Note: This is an edited form of a press release from Biogen. To read the original release in its entirety, click here.  New clinical data support the long-term safety and efficacy of ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in people with severe hemophilia B treated for up to two years, Biogen announced on […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.